Clinical Aspects and Treatments for Pediatric Inflammatory Bowel Diseases.
10.5223/pghn.2019.22.1.50
- Author:
Jin Soo MOON
1
Author Information
1. Department of Pediatrics, Seoul National University Children's Hospital, Seoul National University College of Medicine, Seoul, Korea. mjschj@snu.ac.kr
- Publication Type:Review
- Keywords:
Pediatrics;
Inflammatory bowel diseases;
Crohn disease;
Ulcerative colitis;
Anti-tumor necrosis factor-α blockers
- MeSH:
Adult;
Biological Products;
Colitis, Ulcerative;
Crohn Disease;
Developing Countries;
Drug-Related Side Effects and Adverse Reactions;
Genetic Predisposition to Disease;
Humans;
Incidence;
Inflammation;
Inflammatory Bowel Diseases*;
Necrosis;
Pediatrics;
Quality of Life;
Risk Factors
- From:Pediatric Gastroenterology, Hepatology & Nutrition
2019;22(1):50-56
- CountryRepublic of Korea
- Language:English
-
Abstract:
The incidence of pediatric inflammatory bowel disease (IBD) is increasing worldwide, especially in the developing countries. It differs from adult disease in clinical manifestations, especially with regard to genetic predisposition in monogenic IBD. Pediatric disease also have a tendency to show more aggressive inflammation and greater extent of lesion. Newer drugs such as anti-tumor necrosis factor α have been known to make a difference in treating pediatric IBD. Recent studies suggested that the patients with high risk factors might have some benefits from earlier use of biologics. To achieve treatment goals such as relieving symptoms, optimizing growth, and improving quality of life while minimizing drug toxicity, more research is needed to develop tools for risk stratification in the use of biologics for pediatric IBD.
